[29C3-29C3];[29D1-29D1];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
29C3;29D1
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Lethal in combination with Df(2L)ED623.
Presence of P+PBac{XP5.WH5}BSC201 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d05793 to be at Release 3 genomic coordinate 8408662 on chromosome arm 2L. The Gene Disruption project determined the insertion site of P{XP}d05793 to be at Release 3 genomic coordinate 8408789 on arm 2L. These insertion sites are predicted to lie in 29C3 on both the Release 3 and Release 4 maps. The insertion site of PBac{WH}CG13088f01520 is predicted to lie in 29D1 on the Release 4 map. Consequently, the cytological breakpoints of Df(2L)BSC201 are predicted to be 29C3;29D1.